Victory Capital Management Inc. Reduces Holdings in Celgene Corporation (CELG)

[ad_1]

Celgene Corporation logoVictory Capital Management Inc. diminished its stake in shares of Celgene Corporation (NASDAQ:CELG) by 17.9% within the 2nd quarter, in line with the corporate in its most up-to-date disclosure with the Securities and Exchange Commission. The institutional investor owned 491,105 shares of the biopharmaceutical firm’s inventory after promoting 106,710 shares throughout the quarter. Victory Capital Management Inc. owned zero.06% of Celgene Corporation price $63,780,00zero on the finish of the newest reporting interval.

Numerous different institutional buyers and hedge funds have additionally modified their holdings of the enterprise. Sowell Financial Services LLC boosted its stake in shares of Celgene Corporation by zero.5% within the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical firm’s inventory price $289,00zero after buying a further 13 shares over the past quarter. South Texas Money Management Ltd. boosted its stake in shares of Celgene Corporation by zero.6% within the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical firm’s inventory price $305,00zero after buying a further 15 shares over the past quarter. Flagship Harbor Advisors LLC boosted its stake in shares of Celgene Corporation by zero.9% within the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical firm’s inventory price $253,00zero after buying a further 18 shares over the past quarter. Savant Capital LLC boosted its stake in shares of Celgene Corporation by zero.9% within the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical firm’s inventory price $305,00zero after buying a further 20 shares over the past quarter. Finally, Keel Point LLC boosted its stake in shares of Celgene Corporation by zero.9% within the first quarter. Keel Point LLC now owns three,103 shares of the biopharmaceutical firm’s inventory price $386,00zero after buying a further 28 shares over the past quarter. 78.92% of the inventory is presently owned by institutional buyers.

CELG has been the subject of numerous latest badysis experiences. Vetr downgraded Celgene Corporation from a “strong-buy” ranking to a “buy” ranking and set a $146.88 goal worth on the inventory. in a badysis report on Tuesday, August 29th. Royal Bank of Canada diminished their goal worth on Celgene Corporation from $166.00 to $148.00 and set a “top pick” ranking on the inventory in a badysis report on Friday, October 27th. Leerink Swann restated a “buy” ranking and issued a $156.00 goal worth on shares of Celgene Corporation in a badysis report on Friday, October 20th. Morgan Stanley minimize their worth goal on Celgene Corporation from $120.00 to $115.00 and set an “underweight” ranking on the inventory in a report on Monday, October 23rd. Finally, Cantor Fitzgerald reiterated a “buy” ranking on shares of Celgene Corporation in a report on Monday, August 28th. One funding badyst has rated the inventory with a promote ranking, eleven have given a maintain ranking, nineteen have issued a purchase ranking and two have badigned a robust purchase ranking to the corporate’s inventory. Celgene Corporation has a consensus ranking of “Buy” and a mean goal worth of $139.64.

Celgene Corporation (NASDAQ CELG) opened at $102.34 on Friday. Celgene Corporation has a one 12 months low of $94.55 and a one 12 months excessive of $147.17. The agency has a market capitalization of $80,574.02, a P/E ratio of 15.99, a P/E/G ratio of zero.79 and a beta of 1.79. The firm has a fast ratio of three.52, a present ratio of three.65 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) final launched its quarterly earnings information on Thursday, October 26th. The biopharmaceutical firm reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $zero.04. Celgene Corporation had a return on fairness of 63.80% and a web margin of 27.36%. The agency had income of $three.29 billion throughout the quarter, in comparison with the consensus estimate of $three.42 billion. During the identical interval final 12 months, the enterprise posted $1.58 EPS. Celgene Corporation’s quarterly income was up 10.2% on a year-over-year foundation. equities badysts predict that Celgene Corporation will publish 6.67 earnings per share for the present fiscal 12 months.

In different Celgene Corporation information, Director Michael D. Casey bought 9,250 shares of the inventory in a transaction on Tuesday, September fifth. The inventory was bought at a mean worth of $139.03, for a complete transaction of $1,286,027.50. Following the sale, the director now owns 9,250 shares within the firm, valued at roughly $1,286,027.50. The sale was disclosed in a authorized submitting with the SEC, which is offered via this hyperlink. Also, insider Terrie Curran bought 1,727 shares of the inventory in a transaction on Monday, September 25th. The shares have been bought at a mean worth of $143.89, for a complete worth of $248,498.03. Following the sale, the insider now owns three,925 shares within the firm, valued at roughly $564,768.25. The disclosure for this sale could be discovered right here. In the final quarter, insiders have bought 20,227 shares of firm inventory price $2,843,956. zero.95% of the inventory is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Victory Capital Management Inc. Reduces Holdings in Celgene Corporation (CELG)” was initially reported by InventoryNewsInstances and is owned by of InventoryNewsInstances. If you’re accessing this story on one other area, it was copied illegally and republished in violation of worldwide trademark and copyright laws. The authorized model of this story could be considered at https://stocknewstimes.com/2017/11/12/celgene-corporation-celg-holdings-reduced-by-victory-capital-management-inc.html.

Celgene Corporation Profile

Celgene Corporation is an built-in international biopharmaceutical firm. The Company, along with its subsidiaries, is engaged within the discovery, improvement and commercialization of therapies for the therapy of most cancers and inflammatory ailments via options in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)




Receive News & Ratings for Celgene Corporation Daily – Enter your electronic mail handle under to obtain a concise day by day abstract of the most recent information and badysts’ scores for Celgene Corporation and badociated corporations with MarketBeat.com’s FREE day by day electronic mail publication.

[ad_2]
Source hyperlink

Leave a Reply

Your email address will not be published.